PMID: 27990751 Takikawa M, et al
Any cloudiness, particles, discoloration, or unusual viscosity indicates potential problems
Improvements in glycemic control are blunted overall in our diabetic patients on antidepressants
Currently in Phase 3 clinical trials, retatrutide demonstrated unprecedented weight loss of up to 24.2% at 48 weeks in the Phase 2 trial published in the New England Journal of Medicine
Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Healthcare providers need to assist in pointing patients to these resources and informing them as the market evolves